Sublingual and Oral Tirzepatide Formulations Do Not Exist
There are no FDA-approved sublingual or oral formulations of tirzepatide—only subcutaneous injectable formulations are available at doses of 5 mg, 10 mg, and 15 mg administered once weekly. 1, 2, 3
Current FDA-Approved Administration
Tirzepatide is exclusively available as subcutaneous injections in single-dose prefilled pens and single-dose vials, with no alternative oral or sublingual delivery systems approved or studied in clinical trials 3, 4
The FDA-approved starting dose is 5 mg weekly subcutaneously, which can be titrated up to 10 mg or 15 mg weekly based on response and tolerability 2
Why This Question May Arise: Confusion with Semaglutide
Semaglutide (a different GLP-1 receptor agonist) does have an oral formulation approved for type 2 diabetes, but this oral version is not approved for obesity management and is distinct from injectable semaglutide 2.4 mg used for weight loss 2
However, even for semaglutide, there is no sublingual formulation—only oral tablets and subcutaneous injections exist 2
Critical Pharmacological Barrier
Tirzepatide binds to the GIP receptor but its affinity for the GLP-1 receptor is approximately five times less than that of endogenous GLP-1, making it a peptide hormone that would be degraded in the gastrointestinal tract if taken orally without specialized formulation technology [1, @10@]
The SURPASS clinical trial program (SURPASS 1-5) exclusively evaluated subcutaneous administration at 5 mg, 10 mg, and 15 mg doses, with no investigation of alternative delivery routes 5, 3, 6, 4
Clinical Implications
Patients seeking tirzepatide therapy must be willing and able to self-administer weekly subcutaneous injections 2, 3
If a patient has needle phobia or cannot tolerate injections, tirzepatide is not an appropriate option—there is no oral equivalent dose conversion available 2
For patients who strongly prefer oral medication, the only GLP-1 receptor agonist with an oral formulation is semaglutide (for diabetes only, not obesity), though it demonstrates slightly lower efficacy compared to injectable formulations 2